Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

August 1, 2027

Study Completion Date

September 1, 2027

Conditions
Heart FailureAcute Decompensated Heart Failure
Interventions
COMBINATION_PRODUCT

Early Discharge with Lasix® ONYU (furosemide injection, for subcutaneous use) using SQIN-Infusor

Each practice group randomized to early discharge with subcutaneous furosemide will provide the patient with prefilled units of Lasix® ONYU furosemide injection containing 80 mg per 2.67 mL in a single-dose prefilled cartridge co-packaged with a single-use Disposable Unit of the Infusor that will be used in conjunction with the reusable unit of the Lasix ONYU Infusor. Dosing based on pre-admission oral furosemide requirements: ≤80mg/day oral furosemide will be given 80mg subcutaneous once daily or \>80mg/day oral furosemide will be given 80mg subcutaneous twice daily. Dosing will be continued until clinical euvolemia is reached.

Trial Locations (2)

75209

University of Texas Southwestern Medical Center, Dallas

75246

Baylor Scott and White Health System, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER